The Bittersweet End of the Biocircuits Dream
Executive SummaryBiocircuits' deal with Becton Dickinson represents the bittersweet end of a long, difficult attempt to develop and market an immunoassay system for the doctor's office.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.